AdminMed

11/03/2025

🔬 Groundbreaking Research: AdminPen™ Enables First-Ever Intradermal Delivery of Novel Psoriasis Treatment
We're thrilled to announce a landmark publication in the European Journal of Pharmaceutics and Biopharmaceutics featuring our AdminPen™ 1200 hollow microneedle array technology!
Researchers from Harvard Medical School, Damanhour University, and Cairo University have achieved a world first: the successful intradermal delivery of teriflunomide-loaded emulsomes (TER-EMLs) for the management of psoriasis using hollow microneedle arrays. This pioneering study by Zewail et al. (2025) demonstrates the transformative potential of our AdminPen™ technology in revolutionizing psoriasis treatment.
Key Quantitative Benefits of AdminPen™ 1200 hollow microneedle array injection devices demonstrated:
✅ 100% pe*******on efficiency - All 43 hollow microneedles achieved complete skin pe*******on, creating corresponding dermal micropores for reliable drug delivery,
✅ Optimal 1100-1200 μm pe*******on depth - Effectively breaches stratum corneum and epidermis layers for direct intradermal therapeutic delivery,
✅ Superior inflammatory control - Achieved near-normal NF-KB levels (1.03 vs 0.95 ng/g in controls) compared to 4.8-fold increase in untreated psoriatic tissue,
✅ 3.5-fold antioxidant preservation - Maintained GSH levels at 4.7 pg/g tissue versus only 1.34 pg/g in positive controls
✅ Minimally invasive design - 1200 μm needle height with off-centered hollow pores ensures painless pe*******on and continuous drug flow.
This research validates AdminPen™ hollow microneedle array injection device as an enabling platform for next-generation dermatological therapeutics, offering patients a minimally invasive alternative to conventional psoriasis treatments with enhanced efficacy and reduced side effects.
Read the full paper:https://www.adminmed.com/files/web/publications/2025-Intradermal-delivery-of-teriflunomide-loaded-emulsomes-using-hollow-microneedles-Zewail.pdf
hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag hashtag

10/31/2025

🚀 Breakthrough Research: AdminPen™ 1200 Revolutionizes Psoriasis Treatment Through Advanced Hollow Microneedle Array Injection Technology! 🚀
We're proud to share that our AdminPen™ 1200 hollow microneedle array injection devices have been featured in groundbreaking research published in the Journal of Drug Targeting, demonstrating exceptional performance in photodynamic therapy for the treatment of psoriasis.
Researchers from Damanhour University in Egypt and Cairo University successfully utilized our AdminPen™ 1200 hollow microneedle array injection technology to deliver hypericin-loaded nanocarriers for the non-invasive management of psoriasis, achieving remarkable therapeutic outcomes.
Outstanding Performance Metrics of AdminPen™ 1200:
✅ 100% Puncture Success Rate - All 43 hollow microneedles successfully created microchannels in human skin, ensuring reliable and consistent drug delivery,
📊 1480 μm Deep Drug Distribution - Achieved nearly 2X deeper drug pe*******on compared to conventional methods (750 μm), enabling therapeutic agents to reach critical skin layers,
🎯 43 High-Density Microneedles in 1 cm² - Optimal array configuration provides comprehensive coverage for efficient intradermal delivery across treatment sites,
📏 1200 μm Precision-Engineered Needles - Ideal length successfully bypasses skin barriers while enabling enhanced drug distribution beyond insertion depth,
💊 Superior Clinical Outcomes - Achieved 4.48-fold reduction in inflammatory markers and normalized antioxidant levels comparable to healthy controls when combined with photodynamic therapy
This research validates AdminPen™ 1200 as a game-changing platform for targeted dermal drug delivery, offering painless, efficient, and highly effective treatment options for challenging skin conditions.
The future of minimally invasive therapeutic delivery is here! 💉✨
📄 Read the full paper: "Combined photodynamic therapy and hollow microneedle approach for effective non-invasive delivery of hypericin" - Journal of Drug Targeting, 2024
https://www.adminmed.com/files/web/publications/2024-Combined-photodynamic-therapy-and-hollow-microneedles-Abbas.pdf

10/03/2023

We look forward to meeting with David Young at GPT-Party this week!

Предприниматель, венчурный инвестор. Соучредитель Davidovs Venture Capital — венчурной фирмы на ранней стадии, основанной сообществом из более чем 75 основателей. Соучредите....

09/13/2023

The international group of our academic clients published the results of using AdminPen™ hollow microneedles liquid injection devices (600, 900, 1200, and 1500 μm), which were referred to as Ho-MNs in the publication, for the intradermal delivery of hypericin lipid nanocapsules (Hy-LNCs) for photodynamic therapy (PDT) against skin cancer.

Heba Abd-El-Azim, Ismaiel A. Tekko, Ahlam Ali, Alyaa Ramadan, Noha Nafee, Nawal Khalafallah, Taifur Rahman, William Mcdaid, Rania G. Aly, Lalitkumar K. Vora, Steven J. Bell, Fiona Furlong, Helen O. McCarthy, Ryan F. Donnelly, "Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer," Journal of Controlled Release, Volume 348, 2022, Pages 849-869.

Here are the identified benefits of using AdminPen™ hollow microneedles liquid injection devices (600, 900, 1200, and 1500 μm):

Efficient Intradermal Delivery: The AdminPen™ hollow microneedles (Ho-MNs) array and an in-house fabricated Ho-MN enabled efficient intradermal delivery of hypericin lipid nanocapsules (Hy-LNCs).

Improved Physicochemical Properties: The Hy-LNCs were successfully formed with desirable properties such as a particle size of 47.76 ± 0.49 nm, PDI of 0.12 ± 0.02, and a high encapsulation efficiency of 99.67% ± 0.35.

Enhanced Photoactivity: The Hy-LNCs demonstrated a 396-fold higher photoactivity compared to free hypericin.

Increased Skin Drug Deposition: The use of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) resulted in a 7-fold higher skin drug deposition of Hy-LNCs.

Greater Cellular Uptake: The Hy-LNCs showed significantly greater cellular uptake and higher photocytotoxicity compared to free hypericin.

Remarkable Anti-tumor Effect: In vivo studies using a n**e mouse model with transplanted tumors revealed that Hy-LNCs delivered by AdminPen™ hollow microneedles liquid injection devices (Ho-MN) exhibited a significant anti-tumor destruction (85.84%) after irradiation with 595 nm.

Promising Approach for Skin Cancer Management: The combination of AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) driven delivery of Hy-LNCs followed by irradiation presents a promising minimally invasive, effective, and site-specific approach for managing non-melanoma skin cancers.

In summary, the AdminPen™ hollow microneedles liquid injection devices (Ho-MNs) offer an efficient and effective method for intradermal delivery of hypericin lipid nanocapsules, enhancing their therapeutic potential in photodynamic therapy against skin cancer.

Click here for Full Text (PDF):

09/13/2023

Our academic clients from Mercer University and Georgia State University used the AdminPatch® 1200 microneedle array system for improving transdermal immunization with microparticulate RSV-F Virus-like Particles, as summarized in the following publication:

D’Sa, Sucheta, Kimberly Braz Gomes, Grace Lovia Allotey-Babington, Cemil Boyoglu, Sang-Moo Kang, and Martin J. D’Souza. 2022. "Transdermal Immunization with Microparticulate RSV-F Virus-like Particles Elicits Robust Immunity" Vaccines 10, no. 4: 584.

Here are the identified benefits of using the AdminPatch® 1200 microneedle array system for improving transdermal immunization with microparticulate RSV-F Virus-like Particles:

Robust Immune Responses: The study demonstrated that the transdermal delivery of RSV-F VLP (with or without MPL®) using the AdminPatch® 1200 microneedle array system has the potential to trigger robust immune responses. The transdermal delivery of RSV-F VLP + MPL® was found to be more effective in clearing lung viral loads and preventing weight loss after an RSV challenge.

Enhanced Vaccine Efficacy: At the cellular level, MPL® augmented the vaccine response in microparticulate form. This was evidenced by higher serum and lung antibody titers and lower lung viral titers in the vaccinated groups.

Non-Invasive and Pain-Free Vaccination: The AdminPatch® 1200 microneedle array system offers a non-invasive and pain-free form of vaccination. Due to the short needle lengths, microneedles do not stimulate the nerve endings in the dermis, making the vaccination process more comfortable for the recipient.

Improved Antigen Presentation and Recognition: The study hypothesized that the transdermal delivery of a novel vaccine via the incorporation of a viral antigen such as the RSV fusion (F) protein VLPs in a polymeric matrix might result in enhanced uptake by immune cells. This could also provide improved antigen presentation and recognition by the immune system.

Advantages of Transdermal Delivery: The transdermal route has gained popularity due to its advantages related to patient compliance, ease of administration, lower doses, and the ability to benefit from the immunocompetence of the skin. In transdermal vaccination, dendritic cells and Langerhans cells residing in the dermis can engulf the antigen, leading to the activation of cellular immunity.

Microneedle Patch Acceptability: The minimally-invasive delivery of vaccines via a microneedle patch, such as the AdminPatch® 1200, would be greatly acceptable for individuals, especially children with a phobia of needles.

In conclusion, the AdminPatch® 1200 microneedle array system offers a promising approach for the transdermal delivery of the RSV-F VLP microparticulate vaccine, potentially leading to robust immune responses and enhanced vaccine efficacy.

Click here for Full Text (PDF):

09/13/2023

AdminPatch 600, 777, and 1200 microneedle arrays were successfully used for the delivery of resveratrol for breast cancer therapy, as shown in the following publication:

Shivaprasad Gadag, Reema Narayan, Archana S. Nayak, Diana Catalina Ardila, Shilpa Sant, Yogendra Nayak, Sanjay Garg, Usha Y. Nayak, "Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy," International Journal of Pharmaceutics, Volume 606, 2021, 120877.

The demonstrated benefits of the AdminPatch 600, 777, and 1200 microneedle arrays (denoted as 600 MN, 777 MN, and 1200 MN in the manuscript) are the following:

Localized Delivery: The microneedle array system facilitates the localized delivery of resveratrol (RVT) to breast tissues. This targeted approach ensures that the drug is delivered directly to the affected area, increasing its therapeutic efficacy.

Improved Permeation: The study found that RVT delivered using the microneedle array AdminPatch 1200 showed a higher permeation of RVT across the skin compared to pure RVT. This suggests that the microneedle system enhances the skin's permeability to the drug.

Reduced Skin Retention: The RVT-NLCs (nanostructured lipid carriers) delivered using the microneedle array AdminPatch 1200 resulted in lower skin retention compared to pure RVT. This means that more of the drug is able to pe*****te deeper tissues rather than remaining on the skin's surface.

Enhanced Anticancer Activity: The RVT-NLCs showed higher anticancer activity on MDA-MB-231 breast cancer cell lines compared to pure RVT. This indicates that the combination of the microneedle system and the nanostructured lipid carriers enhances the drug's ability to combat cancer cells.

Inhibition of Cancer Cell Migration: The RVT-NLCs were found to inhibit the migration of MDA-MB-231 breast cancer cell lines. This suggests that the treatment not only kills cancer cells but also prevents them from spreading.

Increased Drug Concentration: Preclinical studies demonstrated that RVT-NLCs delivered via microneedles resulted in a remarkable increase in the Cmax (maximum serum concentration), Tmax (time to reach maximum concentration), and AUC0-inf (area under the curve, indicating overall drug exposure). Additionally, there was a higher localization of the drug in breast tissue compared to pure RVT administered orally.

Effective Strategy for Breast Cancer Therapy: The results suggest that administering RVT-NLCs using the AdminPatch microneedle array system is an effective strategy for localized delivery of RVT for breast cancer therapy.

The AdminPatch microneedle arrays, specifically the AdminPatch 600, AdminPatch 777, and AdminPatch 1200, offer several benefits in the delivery of resveratrol for breast cancer therapy. These benefits include improved drug permeation, reduced skin retention, enhanced anticancer activity, and increased drug concentration in the target area.

Click here for Full Text (PDF):

01/04/2021

The World Economic Forum and Scientific American magazine recognize microneedle technology as one of the top 10 emerging technologies of 2020:

Want to know about the tech set to change the world in the near future? This list is a good place to start.

04/05/2020

AdminMed is a medical device company producing an AdminPen microneedle array injection device. AdminPen has been used to amplify the efficacy of cancer microparticulate vaccines several times (4-16 times!) in comparison to the same vaccine injected using a traditional needle.

AdminPen is expected to amplify the efficacy of COVID-19 vaccines as well and it the only available platform which allows injecting liquid vaccine uniformly into a 1cm2 area of the skin without any need for lengthy reformulation process required by dissolvable microneedle technology.

The vaccine will be delivered through a finger size patch with micro-needles that will dissolve into the skin.

06/13/2019

AdminMed has presented Advanced microneedle products at the recent prestigious 2019 Drug Delivery West Conference in San Francisco, CA. AdminMed, a leading microneedle array company, is producing and selling several hollow metal microneedle array devices in the full spectrum of various sizes. AdminPen injection devices allow intradermal injections over 1 cm2 skin area for more effective and painless delivery of immunotherapies and all other injectable formulations Including therapeutic peptides, proteins, antibodies, and nucleotides. AdminStamp devices perforate skin for improving the absorption of topical formulations. AdminPatch® microneedle patches enable delivering any APIs transdermally using conventional drug-in-adhesive formulations:

https://theconferenceforum.org/conferences/drug-delivery-west/2019-agenda/ -79939-tab

May 6 – 7, 2019 | Marines’ Memorial Club and Hotel, San Francisco, CA, USA

05/21/2018

AdminMed is selected to present at 2018 Drug Delivery Design & Partnering Meeting in San Francisco, CA. Dr. Vadim Yuzhakov presents "AdminMed hollow metal microneedle array devices for painless intradermal injections over the large skin area and more effective transdermal drug delivery" on May 21:
http://theconferenceforum.org/conferences/drug-delivery-west/agenda/

03/28/2018

Great news!

The trial is part of a gathering wave of research into immunotherapy, a type of treatment that fights cancer by using the body's immune system to attack tumors.